Tofacitinib and esophageal-related manifestations in systemic sclerosis: a retrospective real-world cohort focused on lower esophageal sphincter pressure changes
Esophageal dysfunction represents one of the most prevalent, treatment-refractory visceral complications of systemic sclerosis (SSc). Janus kinase (JAK) inhibitors exhibit anti-inflammatory and antifibrotic effects against skin and interstitial lung lesions in SSc, yet evidence linking JAK inhibition to esophagea...